<PAGE>
<PAGE>
Commission File Number: 33-42880
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12B-25
NOTIFICATION OF LATE FILING
(Check One):
[ ] Form 10-K [ ] Form 11-K [ ] Form 20-F
[X] Form 10-Q [ ] Form N-SAR
For Period Ended: June 30, 1997
[ ]Transition Report on Form 10-K
[ ]Transition Report on Form 20-F
[ ]Transition Report on Form 11-K
[ ]Transition Report on Form 10-Q
[ ]Transition Report on Form N-SAR
For the Transition Period Ended:
---------------------------------------
- --------------------------------------------------------------------------------
Read Attached Instruction Sheet Before Preparing Form. Please Print or
Type.
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
- --------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
-----------------------------------------------------------------------
-----------------------------------------------------------------------
- --------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
- --------------------------------------------------------------------------------
Full Name of Registrant: Vivax Medical Corporation
Former Name if Applicable: Nova Technologies, Inc.
545 Middle Street
-----------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Bristol, CT 06010
-----------------------------------------------------------------------
City, State and Zip Code
- --------------------------------------------------------------------------------
PART II -- RULES 12B-25 (B) AND (C)
- --------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
<PAGE>
<PAGE>
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion
thereof will be filed on or before the 15th calendar day
following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following
the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
- --------------------------------------------------------------------------------
PART III -- NARRATIVE
- --------------------------------------------------------------------------------
State below in reasonable detail the reasons why Form 10-K, 20-F, 10-Q, N-SAR
or the transition report or portion thereof could not be filed within the
prescribed period.
(Attach Extra Sheets if Needed)
Registrant was unable to file Form 10-Q due to an inability to timely
obtain all information to make full and complete disclosure of its financial
results.
- --------------------------------------------------------------------------------
PART IV -- OTHER INFORMATION
- --------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification:
David P. Tuttle (203) 862-2396
-----------------------------------------------------------------------
(Name) (Area Code)(Telephone Number)
(2) Have all other periodic reports required under section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
[X]Yes [ ]No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
[X]Yes [ ]No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
-2-
<PAGE>
<PAGE>
Vivax Medical Corportion
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date August 13, 1997 By /s/ Stephen M. Fisher
------------- -----------------------------
Stephen M. Fisher
President
-3-
<PAGE>
<PAGE>
ATTACHMENT TO FORM 12B-25
of
Vivax Medical Corporation
PART IV (3)
It is anticipated that the Registrant's earnings statement to be included with
its Form 10-Q will reflect a net loss for the six month period of approximately
$900,000 compared to a net loss for its prior six month period of $799,000.
The change in results of operations is due primarily to increases in general
and administrative, interest and manufacturing overhead expenses which were
partially offset by increased sales resulting from the acquisition of
Comed Systems, Inc. (now known as Vivax Medical Services, Inc.) on June 14,
1996, as well as increased sales in its original operations.
-4-
